Antitrust and Consumer Protection
Competition: Winter 2017-18, Vol. 27, No. 1
Content
- Antitrust's Hidden Hook In Drug Price Increases
- Certificates of Public Advantage: Bypassing the Ftc In Healthcare Mergers?
- Chair's Column
- Digital Health Privacy: Old Laws Meet New Technologies
- Editor's Note
- Empirical Evidence of Drug Companies Using Citizen Petitions To Hold Off Competition
- Masthead
- Rethinking Healthcare Data Breach Litigation
- The Efficiencies Defenestration: Are Regulators Throwing Valid Healthcare Efficiencies Out the Window?
- The Proximate Cause Requirement In Private Reverse Payment Antitrust Litigation
- Uncertainty and Scientific Complexity: An Introduction To Economic Forces That Drive Current Debates In Healthcare Antitrust
- What Past Agency Actions Say About Complexity In Merger Remedies, With An Application To Generic Drug Divestitures
- Where Art Thou, Efficiencies? the Uncertain Role of Efficiencies In Merger Review
- Causation Principles In Pharmaceutical Antitrust Litigation
CAUSATION PRINCIPLES IN PHARMACEUTICAL ANTITRUST LITIGATION
By Steve D. Shadowen1
Antitrust plaintiffs bring private claims in the pharmaceutical arena that arise from two recurring sets of facts in which brand-drug manufacturers allegedly delay or impair competition from generic-drug manufacturers. In "exclusion payment" or "pay-for-delay" antitrust cases, plaintiffs allege that the brand manufacturer, in the context of settling patent litigation, paid the generic manufacturer to withdraw its challenge to the patent and delay entry into the market. In "product-hopping" cases, plaintiffs allege that the brand manufacturer reformulated its product and switched the built-up base of prescriptions from the original to the reformulated product, in order to shield the prescription base from automatic generic substitution.
Courts are well along in establishing the rules for liability in exclusion-payment cases.2 Product-hopping liability rules are currently less well defined, but the broad outlines are coming into view.3 With liability standards established or on the horizon, the locus of contention in private litigation is increasingly shifting to causation: what evidence must plaintiffs adduce in order to permit a jury to conclude that the antitrust violation caused the injury for which plaintiffs seek recovery?
Borrowing from the common law of torts, courts in antitrust cases apply the familiar rule that plaintiffs must prove that the violation was a "material" or "substantial" cause of the injury. This is a different inquiry than determining the quantum of antitrust damage that the plaintiffs sustained. In determining damages, the plaintiffs compare the price that they actually paid to the price that they would have paid absent the violationâa comparison of the "actual world" to the "but-for world." This requires plaintiffs to offer a reconstruction of what likely would have happened absent the violation. This is not the relevant analytical framework for determining whether the violation likely caused an injury to plaintiffs. In determining causation, the jury considers the nature of the violation and the injury that actually occurred, and then makes a common-sense judgment about whether the violation likely caused the injury. For causation, plaintiffs need not offer any reconstructed "but-for world."